FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andrew Berchuck

Research Profile

Disorders

Concepts & Ideas

Physiology

Procedures

Chemicals & Drugs

Anatomy

Tumor Cells, Cultured

Genes & Molecular Sequences

Co-author Network

Publications

TOP 3
Gregory P Sfakianos; Regina Whitaker; Liudmila Akushevich; Edwin S Iversen; Jeffrey R Marks; Susan Murphy; Joellen M Schildkraut; Andrew Berchuck
Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues.
Delores J Grant; Cathrine Hoyo; Edwin S Iversen; Jeffrey Marks; Lucy Akushevich; Andrew Berchuck; Regina Whitaker; Joellen M Schildkraut
Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women.
Karuna Garg; Douglas A Levine; Narciso Olvera; Nikolaus Schultz; Angeles Alvarez Secord; Andrew Berchuck; Maria Bisogna; Ethan Cerami; Fanny Dao; Robert A Soslow
BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andrew Berchuck (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Gregory P Sfakianos; Regina Whitaker; Liudmila Akushevich; Edwin S Iversen; Jeffrey R Marks; Susan Murphy; Joellen M Schildkraut; Andrew Berchuck
Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues.
Gynecologic oncology 2013;129(1):159-64.
2013: Delores J Grant; Cathrine Hoyo; Edwin S Iversen; Jeffrey Marks; Lucy Akushevich; Andrew Berchuck; Regina Whitaker; Joellen M Schildkraut
Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women.
Gynecologic oncology 2013;129(1):173-8.
2013: Karuna Garg; Douglas A Levine; Narciso Olvera; Nikolaus Schultz; Angeles Alvarez Secord; Andrew Berchuck; Maria Bisogna; Ethan Cerami; Fanny Dao; Robert A Soslow
BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
The American journal of surgical pathology 2013;37(1):138-46.
2012: Angeles Alvarez Secord; Deanna K Teoh; Miao Yu; William T Barry; Andrew Berchuck; Gloria Broadwater; Laura J Havrilesky; Johnathan Lancaster; Paula S Lee; Robert M Wenham
A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(19):5489-98.
2012: Andrew Berchuck
Genetic testing in ovarian cancer: getting better, and maybe not just for disease susceptibility anymore.
Obstetrics and gynecology 2012;120(2 Pt 1):221-2.
2012: Angeles Alvarez Secord; Andrew Berchuck; Robert V Higgins; Robert W Holloway; Matthew F Kohler; George S Lewandowski; Lawrence R Nycum; Larry Puls; Fidel A Valea; Laura Havrilesky
A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Cancer 2012;118(13):3283-93.
2012: Junzo P Chino; Ellen Jones; Angeles Alvarez Secord; Andrew Berchuck; Laura Havrilesky
The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer.
International journal of radiation oncology, biology, physics 2012;82(5):1872-9.
2012: Andrew Berchuck; Angeles Alvarez-Secord; Laura Havrilesky
Minimally invasive surgery for endometrial cancer: the horse is already out of the barn.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(7):681-2.
2012: Kristin L White; Hannah P Yang; Andrew Berchuck; Michael J Birrer; Bridget Charbonneau; Mine S Cicek; Julie M Cunningham; Brooke L Fridley; Montserrat Garcia-Closas; Simon A Gayther; Ellen L Goode; Edwin S Iversen; Rachel T Palmieri; Paul P D Pharoah; Catherine M Phelan; Susan J Ramus; David N Rider; Joellen M Schildkraut; Thomas A Sellers; Honglin Song; Rebecca Sutphen; Jonathan Tyrer; Robert A Vierkant; Nicolas Wentzensen
Ovarian cancer risk associated with inherited inflammation-related variants.
Cancer research 2012;72(5):1064-9.
2012: Kristen N Stevens; Rebecca Sutphen; Ya-Yu Tsai; Robert A Vierkant; Xianshu Wang; Sebastian M Armasu; Andrew Berchuck; Michael J Birrer; Zachary S Fredericksen; Brooke L Fridley; Ellen L Goode; Linda E Kelemen; Steven A Narod; Catherine M Phelan; Joellen M Schildkraut; Thomas A Sellers; Fergus J Couch
Common variation in Nemo-like kinase is associated with risk of ovarian cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2012;21(3):523-8.
2012: Gustavo Rodriguez; M Sharon Stack; Larry G Thaete; Jane M Turbov; Andrew Berchuck; Jean A Hurteau; Catherine P Barry
Nonsteroidal antiinflammatory drugs and progestins synergistically enhance cell death in ovarian epithelial cells.
American journal of obstetrics and gynecology 2012;206(3):253.e1-9.
2012: Jay E Allard; Andrew Berchuck; Jeff Boyd; Gadisetti V R Chandramouli; Thomas P Conrads; Brian L Hood; Tracy Litzi; G Larry Maxwell; Yutaka Shoji; Katherine Stagliano; John Risinger
Analysis of PSPHL as a Candidate Gene Influencing the Racial Disparity in Endometrial Cancer.
Frontiers in oncology 2012;2():65.
2012: Linda E Kelemen; Catherine M Phelan; Joellen M Schildkraut; Ernest K Amankwah; Andrew Berchuck; Julie M Cunningham; Irina Dinu; Brooke L Fridley; Ellen L Goode; Edwin S Iversen; Ya-Yu Tsai; Robert A Vierkant; Qinggang Wang; Thomas A Sellers
Regular Multivitamin Supplement Use, Single Nucleotide Polymorphisms in ATIC, SHMT2, and SLC46A1, and Risk of Ovarian Carcinoma.
Frontiers in genetics 2012;3():33.
2011: Amy E Bondurant; Zhiqing Huang; Lauren R Simel; Regina S Whitaker; Andrew Berchuck; Susan Murphy
Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.
Gynecologic oncology 2011;123(3):581-7.
2011: Douglas C Marchion; Carolina Moreno; Said Sebti; Xiaomang B Stickles; Dan Su; Robert M Wenham; Yin Xiong; Lihua Li; Sachin M Apte; Nisha Bansal; Andrew Berchuck; Elona Bicaku; Gregory C Bloom; Dung-Tsa Chen; Ning Chen; Hye Sook Chon; Hope M Cottrill; Steven Eschrich; William J Fulp; Jesus Gonzalez-Bosquet; Ardeshir Hakam; Patricia L Judson; Siddharth G Kamath; Johnathan M Lancaster
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(19):6356-66.
2011: Steven J Skates; Patrick M Sluss; Linda Van Le; Phuong Mai; Susan G Nayfield; Stacy Nerenstone; William Newland; Marion Piedmonte; Gustavo C Rodriguez; John O Schorge; Deborah K Armstrong; Masoud Azodi; Mack Barnes; Andrew Berchuck; Wendy Brewster; Saundra S Buys; David E Cohn; Mary B Daly; Susan A Davidson; Susan M Domchek; Charles W Drescher; Carol J Fabian; Dianne M Finkelstein; Mark H Greene; Nora K Horick; Ira R Horowitz; Claudine Isaacs; Carol H Kasten; Noah D Kauff; Karen Lu
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.
Cancer prevention research (Philadelphia, Pa.) 2011;4(9):1401-8.
2011: Deanna Teoh; Fidel A Valea; Angeles Alvarez Secord; Andrew Berchuck; Paula S Lee; William J Lowery; Evan R Myers; Gregory P Sfakianos; Laura Havrilesky
Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer.
Gynecologic oncology 2011;122(3):467-72.
2011: Jason C Barnett; Andrew Berchuck; Amy E Bondurant; Nicole D Fleming; Laura Havrilesky; Paula S Lee; Angeles Alvarez Secord; Fidel A Valea
Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer.
American journal of obstetrics and gynecology 2011;205(2):143.e1-6.
2011: G Larry Maxwell; Brian L Hood; Roger Day; Uma Chandran; David Kirchner; V S Kumar Kolli; Nicolas W Bateman; Jay Allard; Caela Miller; Mai Sun; Melanie S Flint; Chris Zahn; Julie Oliver; Subhadra Banerjee; Tracy Litzi; Anil Parwani; Glenn Sandburg; Scott Rose; Michael J Becich; Andrew Berchuck; Elise Kohn; John Risinger; Thomas P Conrads
Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation.
Gynecologic oncology 2011;121(3):586-94.
2011: Ellen L Goode; Kristin L White; Robert A Vierkant; Catherine M Phelan; Julie M Cunningham; Joellen M Schildkraut; Andrew Berchuck; Melissa C Larson; Brooke L Fridley; Janet E Olson; Penelope M Webb; Xiaoqing Chen; Jonathan Beesley; Georgia Chenevix-Trench; Thomas A Sellers
Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk.
Molecular carcinogenesis 2011;50(5):397-402.
2011: Andrew Berchuck; Mark H. Einstein
Prevention and early detection of cancer.
Gynecologic oncology 2011;121(1):1.
2011: Donna K Carver; H John Barnes; Kenneth E Anderson; James N Petitte; Regina Whitaker; Andrew Berchuck; Gustavo Rodriguez
Reduction of ovarian and oviductal cancers in calorie-restricted laying chickens.
Cancer prevention research (Philadelphia, Pa.) 2011;4(4):562-7.
2011: Deanna Teoh; Tina A Ayeni; Jennifer M Rubatt; David J Adams; Lisa Grace; Mark D Starr; William T Barry; Andrew Berchuck; Susan Murphy; Angeles Alvarez Secord
Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.
Gynecologic oncology 2011;121(1):187-92.
2011: Laura Havrilesky; Gillian D Sanders; Shalini L Kulasingam; Junzo P Chino; Andrew Berchuck; Jeffrey R Marks; Evan Myers
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction.
Cancer 2011;117(3):545-53.
2011: Anil Potti; Holly K Dressman; Andrea Bild; Richard F Riedel; Gina Chan; Robyn Sayer; Janiel Cragun; Hope Cottrill; Michael J Kelley; Rebecca Petersen; David Harpole; Jeffrey Marks; Andrew Berchuck; Geoffrey S Ginsburg; Phillip Febbo; Johnathan Lancaster; Joseph R Nevins
Retraction: Genomic signatures to guide the use of chemotherapeutics.
Nature medicine 2011;17(1):135.
2011: Noriomi Matsumura; Zhiqing Huang; Seiichi Mori; Tsukasa Baba; Shingo Fujii; Ikuo Konishi; Edwin S Iversen; Andrew Berchuck; Susan Murphy
Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer.
Genome research 2011;21(1):74-82.
2011: Aimee M Near; Anna H Wu; Claire Templeman; David J Van Den Berg; Jennifer A Doherty; Mary Anne Rossing; Ellen L Goode; Julie M Cunningham; Robert A Vierkant; Brooke L Fridley; Georgia Chenevix-Trench; Penelope M Webb; Susanne Krüger Kjaer; Estrid Hogdall; Simon A Gayther; Susan J Ramus; Usha Menon; Aleksandra Gentry-Maharaj; Joellen M Schildkraut; Patricia G Moorman; Rachel T Palmieri; Roberta B Ness; Kirsten B Moysich; Daniel W Cramer; Kathryn L Terry; Allison F Vitonis; Malcolm C Pike; Andrew Berchuck; Celeste L Pearce
Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort.
Fertility and sterility 2011;95(1):40-5.
2010: Amy H Wallace; Laura Havrilesky; Fidel A Valea; Jason C Barnett; Andrew Berchuck; Evan Myers
Projecting the need for gynecologic oncologists for the next 40 years.
Obstetrics and gynecology 2010;116(6):1366-72.
2010: Jonathan S Berek; Eva Chalas; Mitchell Edelson; David H Moore; William M Burke; William A Cliby; Andrew Berchuck
Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer.
Obstetrics and gynecology 2010;116(3):733-43.
2010: Dimitra Dafou; Barbara Grun; John Sinclair; Kate Lawrenson; Elizabeth C Benjamin; Estrid Hogdall; Susanne Kruger-Kjaer; Lise Christensen; Heidi M Sowter; Ahmed Al-Attar; Richard Edmondson; Stephen Darby; Andrew Berchuck; Peter W Laird; Celeste L Pearce; Susan J Ramus; Ian J Jacobs; Simon A Gayther
Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers.
Neoplasia (New York, N.Y.) 2010;12(7):579-89.
2010: Eiji Kondoh; Seiichi Mori; Ken Yamaguchi; Tsukasa Baba; Noriomi Matsumura; J Cory Barnett; Regina S Whitaker; Ikuo Konishi; Shingo Fujii; Andrew Berchuck; Susan Murphy
Targeting slow-proliferating ovarian cancer cells.
International journal of cancer. Journal international du cancer 2010;126(10):2448-56.
2010: Paula S Lee; Vanessa S Teaberry; Amy E Bland; Zhiqing Huang; Regina S Whitaker; Tsukasa Baba; Shingo Fujii; Angeles Alvarez Secord; Andrew Berchuck; Susan Murphy
Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
International journal of cancer. Journal international du cancer 2010;126(6):1378-89.
2010: Jason C Barnett; Sarah M Bean; Regina S Whitaker; Eiji Kondoh; Tsukasa Baba; Shingo Fujii; Jeffrey R Marks; Holly K Dressman; Susan Murphy; Andrew Berchuck
Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype.
Gynecologic oncology 2010;116(3):556-62.
2010: Kristin L White; Thomas A Sellers; Brooke L Fridley; Robert A Vierkant; Catherine M Phelan; Ya-Yu Tsai; Kimberly R Kalli; Andrew Berchuck; Edwin S Iversen; Lynn C Hartmann; Mark Liebow; Sebastian Armasu; Zachary Fredericksen; Melissa C Larson; David Duggan; Fergus J Couch; Joellen M Schildkraut; Julie M Cunningham; Ellen L Goode
Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer.
Twin research and human genetics : the official journal of the International Society for Twin Studies 2010;13(1):43-56.
2010: Marcus Q Bernardini; Tsukasa Baba; Paula S Lee; Jason C Barnett; Gregory P Sfakianos; Angeles Alvarez Secord; Susan Murphy; Edwin Iversen; Jeffrey R Marks; Andrew Berchuck
Expression signatures of TP53 mutations in serous ovarian cancers.
BMC cancer 2010;10():237.
2010: Joellen M Schildkraut; Edwin S Iversen; Melanie A Wilson; Merlise A Clyde; Patricia G Moorman; Rachel T Palmieri; Regina Whitaker; Rex C Bentley; Jeffrey R Marks; Andrew Berchuck
Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer.
PloS one 2010;5(4):e10061.
2010: Abraham Peedicayil; Robert A Vierkant; Lynn C Hartmann; Brooke L Fridley; Zachary S Fredericksen; Kristin L White; Elaine A Elliott; Catherine M Phelan; Ya-Yu Tsai; Andrew Berchuck; Edwin S Iversen; Fergus J Couch; Prema Peethamabaran; Melissa C Larson; Kimberly R Kalli; Matthew L Kosel; Viji Shridhar; David N Rider; Mark Liebow; Julie M Cunningham; Joellen M Schildkraut; Thomas A Sellers; Ellen L Goode
Risk of ovarian cancer and inherited variants in relapse-associated genes.
PloS one 2010;5(1):e8884.
2010: Jason C Barnett; Sarah M Bean; John M Nakayama; Eiji Kondoh; Susan Murphy; Andrew Berchuck
High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer.
Obstetrics and gynecology 2010;115(1):49-54.
2009: Elizabeth Jewell; Kathleen M Darcy; Alan Hutson; Paula S Lee; Laura Havrilesky; Lisa A Grace; Andrew Berchuck; Angeles Alvarez Secord
Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.
Gynecologic oncology 2009;115(3):424-9.
2009: Julie M Cunningham; Robert A Vierkant; Thomas A Sellers; C Phelan; D N Rider; Mark Liebow; Joellen M Schildkraut; Andrew Berchuck; Fergus J. Couch; Xianshu Wang; Brooke L Fridley; A Gentry-Maharaj; Usha Menon; Estrid Hogdall; Susanne Krüger Kjaer; A Whittemore; Richard A DiCioccio; H Song; Simon A Gayther; S J Ramus; P D P Pharaoh; Ellen L Goode
Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.
British journal of cancer 2009;101(8):1461-8.
2009: Paula S Lee; Amy Bland; Fidel A Valea; Laura Havrilesky; Andrew Berchuck; Angeles Alvarez Secord
Robotic-assisted laparoscopic gynecologic procedures in a fellowship training program.
JSLS : Journal of the Society of Laparoendoscopic Surgeons / Society of Laparoendoscopic Surgeons 2009;13(4):467-72.
2009: Honglin Song; Susan J Ramus; Jonathan Tyrer; Kelly L Bolton; Aleksandra Gentry-Maharaj; Eva Wozniak; Hoda Anton-Culver; Jenny Chang-Claude; Daniel W Cramer; Richard DiCioccio; Thilo Dörk; Ellen L Goode; Marc T Goodman; Joellen M Schildkraut; Thomas Sellers; Laura Baglietto; Matthias W Beckmann; Jonathan Beesley; Jan Blaakaer; Michael E Carney; STEPHEN CHANOCK; Zhihua Chen; Julie M Cunningham; Ed Dicks; Jennifer A Doherty; Matthias Dürst; Arif B Ekici; David Fenstermacher; Brooke L Fridley; Graham Giles; Martin E Gore; Immaculata DeVivo; Peter Hillemanns; Claus Hogdall; Estrid Hogdall; Edwin S Iversen; Ian J Jacobs; Anna Jakubowska; Dong Li; Jolanta Lissowska; Jan Lubiński; Galina Lurie; Valerie McGuire; John McLaughlin; Krzysztof Medrek; Patricia G Moorman; Kirsten Moysich; Steven Narod; Catherine Phelan; Carole Pye; Harvey Risch; Ingo B Runnebaum; Gianluca Severi; Melissa Southey; Daniel O Stram; Falk C Thiel; Kathryn L Terry; Ya-Yu Tsai; Shelley S Tworoger; David J Van Den Berg; Robert A Vierkant; Shan Wang-Gohrke; Penelope M Webb; Lynne R Wilkens; Anna H Wu; Hannah Yang; Wendy Brewster; Argyrios Ziogas; Richard Houlston; Ian Tomlinson; Alice S Whittemore; Mary Anne Rossing; Bruce A J Ponder; Celeste Leigh Pearce; Roberta B Ness; Usha Menon; Susanne Krüger Kjaer; Jacek Gronwald; Montserrat Garcia-Closas; Peter A Fasching; Douglas F Easton; Georgia Chenevix-Trench; Andrew Berchuck; Paul D P Pharoah; Simon A Gayther
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.
Nature genetics 2009;41(9):996-1000.
2009: Patricia G Moorman; Rachel T Palmieri; Lucy Akushevich; Andrew Berchuck; Joellen M Schildkraut
Ovarian cancer risk factors in African-American and white women.
American journal of epidemiology 2009;170(5):598-606.
2009: X Ding; A B Mohd; Z Huang; T Baba; M Q Bernardini; H Kim Lyerly; Andrew Berchuck; Susan Murphy; A B Buermeyer; Gayathri Devi
MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition.
British journal of cancer 2009;101(2):269-77.
2009: Marcus Q Bernardini; Taymaa May; Mahmoud A Khalifa; Amy E Bland; Sharon Nofech-Mozes; Andrew Berchuck; Allan Covens; Laura Havrilesky
Evaluation of two management strategies for preoperative grade 1 endometrial cancer.
Obstetrics and gynecology 2009;114(1):7-15.
2009: Andrew Berchuck
Microarray analysis of gene expression in gynecologic cancers--still only the beginning.
Gynecologic oncology 2009;114(1):1-2.
2009: Honglin Song; Susan J Ramus; Susanne Krüger Kjaer; Richard A DiCioccio; Georgia Chenevix-Trench; Celeste Leigh Pearce; Estrid Hogdall; Alice S Whittemore; Valerie McGuire; Claus Hogdall; Jan Blaakaer; Anna H Wu; David J Van Den Berg; Daniel O Stram; Usha Menon; Aleksandra Gentry-Maharaj; Ian J Jacobs; Penny M Webb; Jonathan Beesley; Xiaoqing Chen; Mary Anne Rossing; Jennifer A Doherty; Jenny Chang-Claude; Shan Wang-Gohrke; Marc T Goodman; Galina Lurie; Pamela J Thompson; Michael E Carney; Roberta B Ness; Kirsten Moysich; Ellen L Goode; Robert A Vierkant; Julie M Cunningham; Stephanie Anderson; Joellen M Schildkraut; Andrew Berchuck; Edwin S Iversen; Patricia G Moorman; Montserrat Garcia-Closas; STEPHEN CHANOCK; Jolanta Lissowska; Louise Brinton; Hoda Anton-Culver; Argyrios Ziogas; Wendy Brewster; Bruce A J Ponder; Douglas F Easton; Simon A Gayther; Paul D P Pharoah
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.
Human molecular genetics 2009;18(12):2297-304.
2009: Peter A Fasching; Simon Gayther; Leigh Pearce; Joellen M Schildkraut; Ellen Goode; Falk Thiel; Georgia Chenevix-Trench; Jenny Chang-Claude; Shan Wang-Gohrke; Susan Ramus; Paul Pharoah; Andrew Berchuck
Role of genetic polymorphisms and ovarian cancer susceptibility.
Molecular oncology 2009;3(2):171-81.
2009: Andrew Berchuck; Edwin S Iversen; Jingqin Luo; Jennifer Clarke; Hisani Horne; Douglas A Levine; Jeff Boyd; Miguel A Alonso; Angeles Alvarez Secord; Marcus Q Bernardini; Jason C Barnett; Todd Boren; Susan Murphy; Holly K Dressman; Jeffrey R Marks; Johnathan M Lancaster
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(7):2448-55.
2009: Joellen M Schildkraut; Ellen L Goode; Merlise A Clyde; Edwin S Iversen; Patricia G Moorman; Andrew Berchuck; Jeffrey R Marks; Jolanta Lissowska; Louise Brinton; Beata Peplonska; Julie M Cunningham; Robert A Vierkant; David N Rider; Georgia Chenevix-Trench; Penelope M Webb; Jonathan Beesley; Xiaoqing Chen; Catherine Phelan; Rebecca Sutphen; Thomas A Sellers; Leigh Pearce; Anna H Wu; David Van Den Berg; David Conti; Christopher K Elund; Rebecca Anderson; Marc T Goodman; Galina Lurie; Michael E Carney; Pamela J Thompson; Simon A Gayther; Susan J Ramus; Ian Jacobs; Susanne Krüger Kjaer; Estrid Hogdall; Jan Blaakaer; Claus Hogdall; Douglas F Easton; Honglin Song; Paul D P Pharoah; Alice S Whittemore; Valerie McGuire; Lydia Quaye; Hoda Anton-Culver; Argyrios Ziogas; Kathryn L Terry; Daniel W Cramer; Susan E Hankinson; Shelley S Tworoger; Brian Calingaert; STEPHEN CHANOCK; Mark Sherman; Montserrat Garcia-Closas
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer.
Cancer research 2009;69(6):2349-57.
2009: Jennifer M Rubatt; Kathleen M Darcy; Alan Hutson; Sarah M Bean; Laura Havrilesky; Lisa A Grace; Andrew Berchuck; Angeles Alvarez Secord
Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
Gynecologic oncology 2009;112(3):469-74.
2009: Noriomi Matsumura; Zhiqing Huang; Tsukasa Baba; Paula S Lee; Jason C Barnett; Seiichi Mori; Jeffrey T Chang; Wen-Lin Kuo; Alison H Gusberg; Regina S Whitaker; Joe Gray; Shingo Fujii; Andrew Berchuck; Susan Murphy
Yin yang 1 modulates taxane response in epithelial ovarian cancer.
Molecular cancer research : MCR 2009;7(2):210-20.
2009: Amy A Hakim; Catherine P Barry; H John Barnes; Kenneth E Anderson; James Petitte; Regina Whitaker; Jonathan M Lancaster; Robert M Wenham; Donna K Carver; Jane Turbov; Andrew Berchuck; Levy Kopelovich; Gustavo Rodriguez
Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
Cancer prevention research (Philadelphia, Pa.) 2009;2(2):114-21.
2009: Celeste L Pearce; A M Near; D J Van Den Berg; S J Ramus; A Gentry-Maharaj; U Menon; S A Gayther; A R Anderson; C K Edlund; A H Wu; X Chen; J Beesley; P M Webb; S K Holt; C Chen; J A Doherty; M A Rossing; A S Whittemore; V McGuire; R A DiCioccio; M T Goodman; G Lurie; M E Carney; L R Wilkens; R B Ness; K B Moysich; R Edwards; E Jennison; S K Kjaer; E Hogdall; C K Hogdall; Ellen L Goode; T A Sellers; R A Vierkant; J M Cunningham; J C Cunningham; J M Schildkraut; Andrew Berchuck; P G Moorman; E S Iversen; D W Cramer; K L Terry; A F Vitonis; L Titus-Ernstoff; H Song; P D P Pharoah; A B Spurdle; H Anton-Culver; Argyrios Ziogas; Wendy Brewster; V Galitovskiy; G Chenevix-Trench
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.
British journal of cancer 2009;100(2):412-20.
2009: T Baba; P A Convery; N Matsumura; Regina S Whitaker; E Kondoh; T Perry; Z Huang; Rex C Bentley; S Mori; S Fujii; Jeffrey R Marks; Andrew Berchuck; Susan Murphy
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Oncogene 2009;28(2):209-18.
2009: Amy E Bland; Brian Calingaert; Angeles Alvarez Secord; Paula S Lee; Fidel A Valea; Andrew Berchuck; John Soper; Laura Havrilesky
Relationship between tamoxifen use and high risk endometrial cancer histologic types.
Gynecologic oncology 2009;112(1):150-4.
2008: Rachel T Palmieri; Melanie A Wilson; Edwin S Iversen; Merlise A Clyde; Brian Calingaert; Patricia G Moorman; Charles Poole; A Rebecca Anderson; Stephanie Anderson; Hoda Anton-Culver; Jonathan Beesley; Estrid Hogdall; Wendy Brewster; Michael E Carney; Xiaoqing Chen; Georgia Chenevix-Trench; Jenny Chang-Claude; Julie M Cunningham; Richard A Dicioccio; Jennifer A Doherty; Douglas F Easton; Christopher K Edlund; Simon A Gayther; Aleksandra Gentry-Maharaj; Ellen L Goode; Marc T Goodman; Susanne Kruger Kjaer; Claus K Hogdall; Michael P Hopkins; Eric L Jenison; Jan Blaakaer; Galina Lurie; Valerie McGuire; Usha Menon; Kirsten B Moysich; Roberta B Ness; Celeste L Pearce; Paul D P Pharoah; Malcolm Pike; Susan J Ramus; Mary Anne Rossing; Honglin Song; Keith Y Terada; David Vandenberg; Robert A Vierkant; Shan Wang-Gohrke; Penelope M Webb; Alice S Whittemore; Anna H Wu; Argyrios Ziogas; Andrew Berchuck; Joellen M Schildkraut
Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008;17(12):3567-72.
2008: Laura Havrilesky; Clark M Whitehead; Jennifer M Rubatt; Robert L Cheek; John Groelke; Qin He; Douglas P Malinowski; Timothy J Fischer; Andrew Berchuck
Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
Gynecologic oncology 2008;110(3):374-82.
2008: Susan J Ramus; Robert A Vierkant; Sharon E Johnatty; Malcolm Pike; David J Van Den Berg; Anna H Wu; Celeste L Pearce; Usha Menon; Aleksandra Gentry-Maharaj; Simon A Gayther; Richard A Dicioccio; Valerie McGuire; Alice S Whittemore; Honglin Song; Douglas F Easton; Paul D P Pharoah; Montserrat Garcia-Closas; STEPHEN CHANOCK; Jolanta Lissowska; Louise Brinton; Kathryn L Terry; Daniel W Cramer; Shelley S Tworoger; Susan E Hankinson; Andrew Berchuck; Patricia G Moorman; Joellen M Schildkraut; Julie M Cunningham; Mark Liebow; Susanne Krüger Kjaer; Estrid Hogdall; Claus Hogdall; Jan Blaakaer; Roberta B Ness; Kirsten B Moysich; Robert P Edwards; Michael E Carney; Galina Lurie; Marc T Goodman; Shan Wang-Gohrke; Silke Kropp; Jenny Chang-Claude; Penelope M Webb; Xiaoqing Chen; Jonathan Beesley; Georgia Chenevix-Trench; Ellen L Goode
Consortium analysis of 7 candidate SNPs for ovarian cancer.
International journal of cancer. Journal international du cancer 2008;123(2):380-8.
2008: Andrew Berchuck
Scientific innovation--pathway to progress in women's cancer.
Gynecologic oncology 2008;109(3):316-22.
2008: Patricia G Moorman; Brian Calingaert; Rachel T Palmieri; Edwin S Iversen; Rex C Bentley; Susan Halabi; Andrew Berchuck; Joellen M Schildkraut
Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women.
American journal of epidemiology 2008;167(9):1059-69.
2008: J D Wright; Angeles Alvarez Secord; T Michael Numnum; Rodney P Rocconi; Matthew A Powell; Andrew Berchuck; Ronald D Alvarez; Randall K Gibb; K Trinkaus; Janet S Rader; David G Mutch
A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18(3):400-6.
2008: Joellen M Schildkraut; Patricia G Moorman; Amy E Bland; Susan Halabi; Brian Calingaert; Regina Whitaker; Paula S Lee; Tyler Elkins-Williams; Rex C Bentley; Jeffrey R Marks; Andrew Berchuck
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008;17(3):585-93.
2008: Celeste L Pearce; A H Wu; S A Gayther; A E Bale; P A Beck; J Beesley; STEPHEN CHANOCK; D W Cramer; R DiCioccio; R Edwards; Z S Fredericksen; M Garcia-Closas; Ellen L Goode; A C Green; L C Hartmann; E Hogdall; S K Kjaer; J Lissowska; V McGuire; F Modugno; K Moysich; R B Ness; S J Ramus; H A Risch; T A Sellers; H Song; D O Stram; K L Terry; P M Webb; D C Whiteman; A S Whittemore; W Zheng; P D P Pharoah; G Chenevix-Trench; Malcolm Pike; J Schildkraut; Andrew Berchuck
Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis.
British journal of cancer 2008;98(2):282-8.
2008: Andrew Berchuck; Joellen M Schildkraut; C Leigh Pearce; Georgia Chenevix-Trench; Paul D Pharoah
Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium.
Advances in experimental medicine and biology 2008;622():53-67.
2007: Zhen Zhang; Yinhua Yu; Fengji Xu; Andrew Berchuck; Carolien Van Haaften-Day; Laura Havrilesky; Henk W A de Bruijn; Ate G J van der Zee; Robert P Woolas; Ian J Jacobs; Steven J Skates; Daniel W Chan; Robert C Bast
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.
Gynecologic oncology 2007;107(3):526-31.
2007: Johnathan M Lancaster; C Bethan Powell; Noah D Kauff; Ilana Cass; Lee-May Chen; Karen H Lu; David G Mutch; Andrew Berchuck; Beth Y Karlan; Thomas J Herzog
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
Gynecologic oncology 2007;107(2):159-62.
2007: Angeles Alvarez-Secord; Laura Havrilesky; Victoria L Bae-Jump; Jeanette Chin; Brian Calingaert; Amy Bland; Teresa Rutledge; Andrew Berchuck; Daniel L Clarke-Pearson; Paola A Gehrig
The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Gynecologic oncology 2007;107(2):285-91.
2007: Jay E Allard; John Risinger; Carl Morrison; Gregory Young; G Scott Rose; Jeff Fowler; Andrew Berchuck; G Larry Maxwell
Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas.
Gynecologic oncology 2007;107(1):52-7.
2007: Andrew Berchuck
Chemotherapy administration for ovarian cancer by gynecologic oncologists and medical oncologists.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3552; author reply 3557-8.
2007: Beth Y Karlan; Andrew Berchuck; David Mutch
The role of genetic testing for cancer susceptibility in gynecologic practice.
Obstetrics and gynecology 2007;110(1):155-67.
2007: Angeles Alvarez Secord; Kathleen M Darcy; Alan Hutson; Paula S Lee; Laura Havrilesky; Lisa A Grace; Andrew Berchuck
Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.
Gynecologic oncology 2007;106(1):221-32.
2007: Louis A Dainty; John Risinger; Carl Morrison; Gadisetti V R Chandramouli; Michael A Bidus; Christopher M Zahn; G Scott Rose; Jeff Fowler; Andrew Berchuck; G Larry Maxwell
Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma.
Gynecologic oncology 2007;105(3):563-70.
2007: Laura Havrilesky; Angeles Alvarez Secord; Victoria L Bae-Jump; Tina Ayeni; Brian Calingaert; Daniel L Clarke-Pearson; Andrew Berchuck; Paola A Gehrig
Outcomes in surgical stage I uterine papillary serous carcinoma.
Gynecologic oncology 2007;105(3):677-82.
2007: Monique A Spillman; Judith Lacy; Susan Murphy; Regina S Whitaker; Lisa A Grace; Vanessa Teaberry; Jeffrey R Marks; Andrew Berchuck
Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.
Gynecologic oncology 2007;105(2):312-20.
2007: Simon A Gayther; Honglin Song; Susan J Ramus; Susan Krüger Kjaer; Alice S Whittemore; Lydia Quaye; Jonathan Tyrer; Danielle Shadforth; Estrid Hogdall; Claus Hogdall; Jan Blaeker; Richard DiCioccio; Valerie McGuire; Penelope M Webb; Jonathan Beesley; Adele C Green; David C Whiteman; Marc T Goodman; Galina Lurie; Michael E Carney; Francesmary Modugno; Roberta B Ness; Robert P Edwards; Kirsten B Moysich; Ellen L Goode; Fergus J. Couch; Julie M Cunningham; Thomas A Sellers; Anna H Wu; Malcolm Pike; Edwin S Iversen; Jeffrey R Marks; Montserrat Garcia-Closas; Louise Brinton; Jolanta Lissowska; Beata Peplonska; Douglas F Easton; Ian Jacobs; bruce ponder; Joellen Schildkraut; Celeste L Pearce; Georgia Chenevix-Trench; Andrew Berchuck; Paul D P Pharoah
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer.
Cancer research 2007;67(7):3027-35.
2007: John Risinger; Gadisetti V R Chandramouli; G Larry Maxwell; Mary Custer; Svetlana Pack; Dmitri Loukinov; Olga Aprelikova; Tracy Litzi; David S Schrump; Susan Murphy; Andrew Berchuck; Victor Lobanenkov; J Carl Barrett
Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1713-9.
2007: Joellen M Schildkraut; Susan Murphy; Rachel T Palmieri; Edwin S Iversen; Patricia G Moorman; Zhiqing Huang; Susan Halabi; Brian Calingaert; Alison Gusberg; Jeffrey R Marks; Andrew Berchuck
Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(3):473-80.
2007: Holly K Dressman; Andrew Berchuck; Gina Chan; Jun Zhai; Andrea Bild; Robyn A Sayer; Janiel M Cragun; Jennifer Clarke; Regina S Whitaker; Lihua Li; Jonathan Gray; Jeffrey Marks; Geoffrey S Ginsburg; Anil Potti; Mike West; Joseph R Nevins; Johnathan M Lancaster
An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(5):517-25.
2007: Angeles Alvarez Secord; Laura Havrilesky; Michael E Carney; John Soper; Daniel L Clarke-Pearson; Gustavo Rodriguez; Andrew Berchuck
Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.
International journal of clinical oncology 2007;12(1):31-6.
2007: Laura Havrilesky; Janiel M Cragun; Brian Calingaert; Angeles Alvarez-Secord; Fidel A Valea; Daniel L Clarke-Pearson; Andrew Berchuck; John Soper
The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer.
Gynecologic oncology 2007;104(2):401-5.
2007: John Soper; Angeles Alvarez Secord; Laura Havrilesky; Andrew Berchuck; Daniel L Clarke-Pearson
Comparison of gracilis and rectus abdominis myocutaneous flap neovaginal reconstruction performed during radical pelvic surgery: flap-specific morbidity.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2007;17(1):298-303.
2006: Anil Potti; Holly K Dressman; Andrea Bild; Richard F Riedel; Gina Chan; Robyn A Sayer; Janiel M Cragun; Hope Cottrill; Michael J Kelley; Rebecca Petersen; David H Harpole; Jeffrey Marks; Andrew Berchuck; Geoffrey S Ginsburg; Phillip G Febbo; Johnathan Lancaster; Joseph R Nevins
Genomic signatures to guide the use of chemotherapeutics.
Nature medicine 2006;12(11):1294-300.
2006: G Larry Maxwell; Joellen M Schildkraut; Brian Calingaert; John Risinger; Louis A Dainty; Polly A Marchbanks; Andrew Berchuck; J Carl Barrett; Gustavo Rodriguez
Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.
Gynecologic oncology 2006;103(2):535-40.
2006: Evan Myers; Laura Havrilesky; Shalini L Kulasingam; Gillian D Sanders; Kathryn E Cline; Rebecca N Gray; Andrew Berchuck; Douglas C McCrory
Genomic tests for ovarian cancer detection and management.
Evidence report/technology assessment 2006;(145):1-100.
2006: Jose G Guillem; William C Wood; Jeffrey F Moley; Andrew Berchuck; Beth Y Karlan; David G Mutch; Robert F Gagel; Jeffrey N Weitzel; Monica Morrow; Barbara L Weber; Francis M Giardiello; Miguel A Rodriguez-Bigas; James Church; Stephen B Gruber; Kenneth Offit
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(28):4642-60.
2006: Jose G Guillem; William C Wood; Jeffrey F Moley; Andrew Berchuck; Beth Y Karlan; David G Mutch; Robert F Gagel; Jeffrey N Weitzel; Monica Morrow; Barbara L Weber; Francis M Giardiello; Miguel A Rodriguez-Bigas; James Church; Stephen B Gruber; Kenneth Offit
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.
Annals of surgical oncology 2006;13(10):1296-321.
2006: Johnathan M Lancaster; Holly K Dressman; Jennifer Clarke; Robyn A Sayer; Martin A Martino; Janiel M Cragun; A H Henriott; Jonathan Gray; Rebecca Sutphen; A Elahi; Regina S Whitaker; M West; Jeffrey R Marks; J R Nevins; Andrew Berchuck
Identification of genes associated with ovarian cancer metastasis using microarray expression analysis.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(5):1733-45.
2006: Johnathan M Lancaster; Robyn A Sayer; Carrie Blanchette; Brian Calingaert; I Konidari; Jonathan Gray; Joellen M Schildkraut; David W Schomberg; Jeffrey R Marks; Andrew Berchuck
High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(4):1529-35.
2006: Christopher V Lutman; Laura Havrilesky; Janiel M Cragun; Angeles Alvarez Secord; Brian Calingaert; Andrew Berchuck; Daniel L Clarke-Pearson; John Soper
Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.
Gynecologic oncology 2006;102(1):92-7.
2006: Angeles Alvarez Secord; Paula S Lee; Kathleen M Darcy; Laura Havrilesky; Lisa A Grace; Jeffrey R Marks; Andrew Berchuck
Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
Gynecologic oncology 2006;101(3):390-7.
2006: Elizabeth Jewell; Angeles Alvarez Secord; T Brotherton; Andrew Berchuck
Use of trastuzumab in the treatment of metastatic endometrial cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(3):1370-3.
2006: Monica Brown Jones; Aletta P Houwink; Brandi K Freeman; Tammy M Greenwood; Jacqueline M Lafky; Wilma L Lingle; Andrew Berchuck; G Lawrence Maxwell; Karl C Podratz; Nita Maihle
The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer.
Journal of the Society for Gynecologic Investigation 2006;13(4):304-11.
2006: Susan Murphy; Zhiqing Huang; Yaqing Wen; Monique A Spillman; Regina S Whitaker; Lauren R Simel; Teresa D Nichols; Jeffrey R Marks; Andrew Berchuck
Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer.
Molecular cancer research : MCR 2006;4(4):283-92.
2006: Ellen Jones; Angeles Alvarez-Secord; Leonard R Prosnitz; Thaddeus V Samulski; James R Oleson; Andrew Berchuck; Daniel L Clarke-Pearson; John Soper; Mark Dewhirst; Zeljko Vujaskovic
Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2006;22(2):161-72.
2006: Andrea Bild; Guang Yao; Jeffrey T Chang; Quanli Wang; Anil Potti; Dawn Chasse; Mary-Beth Moore Joshi; David H Harpole; Johnathan M Lancaster; Andrew Berchuck; John Olson; Jeffrey R Marks; Holly K Dressman; Mike West; Joseph R Nevins
Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
Nature 2006;439(7074):353-7.
2006: Christopher Kingsley; Wen-Lin Kuo; Daniel Polikoff; Andrew Berchuck; Joe Gray; Ajay N Jain
Magellan: a web based system for the integrated analysis of heterogeneous biological data and annotations; application to DNA copy number and expression data in ovarian cancer.
Cancer informatics 2006;2():10-21.
2006: John Risinger; Gadisetti V R Chandramouli; G Larry Maxwell; Tracy Litzi; Andrew Berchuck; Asad Umar
Gene expression analysis of tumor infiltrating lymphocyte markers in endometrial cancers indicates no significant increases in those cases with microsatellite instability.
Cancer biomarkers : section A of Disease markers 2006;2(1-2):61-8.
2006: Zhiqing Huang; Yaqing Wen; Ruby Shandilya; Jeffrey R Marks; Andrew Berchuck; Susan Murphy
High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer.
Nucleic acids research 2006;34(2):555-63.
2006: Michael A Bidus; John Risinger; Gadisetti V R Chandramouli; Louis A Dainty; Tracy Litzi; Andrew Berchuck; J Carl Barrett; G Larry Maxwell
Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(1):83-8.
2006: Joellen M Schildkraut; Patricia G Moorman; Susan Halabi; Brian Calingaert; Jeffrey R Marks; Andrew Berchuck
Analgesic drug use and risk of ovarian cancer.
Epidemiology (Cambridge, Mass.) 2006;17(1):104-7.
2005: Laura Havrilesky; Janiel M Cragun; Brian Calingaert; Ingrid Synan; Angeles Alvarez Secord; John Soper; Daniel L Clarke-Pearson; Andrew Berchuck
Resection of lymph node metastases influences survival in stage IIIC endometrial cancer.
Gynecologic oncology 2005;99(3):689-95.
2005: Cathrine Hoyo; Andrew Berchuck; Susan Halabi; Rex C Bentley; Patricia G Moorman; Brian Calingaert; Joellen M Schildkraut
Anthropometric measurements and epithelial ovarian cancer risk in African-American and White women.
Cancer causes & control : CCC 2005;16(8):955-63.
2005: Rebecca T Marquez; Keith A Baggerly; Andrea P Patterson; Jinsong Liu; Russell R Broaddus; Michael Frumovitz; E Neely Atkinson; David I Smith; Lynn Hartmann; David Fishman; Andrew Berchuck; Regina Whitaker; David M Gershenson; Gordon B Mills; Robert C Bast; Karen H Lu
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6116-26.
2005: Patricia G Moorman; Joellen M Schildkraut; Brian Calingaert; Susan Halabi; Andrew Berchuck
Menopausal hormones and risk of ovarian cancer.
American journal of obstetrics and gynecology 2005;193(1):76-82.
2005: John Risinger; G Larry Maxwell; Gadisetti V R Chandramouli; Olga Aprelikova; Tracy Litzi; Asad Umar; Andrew Berchuck; J Carl Barrett
Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling.
Cancer research 2005;65(12):5031-7.
2005: Angeles Alvarez-Secord; Ellen Jones; Carol A Hahn; William P Petros; D Yu; Laura Havrilesky; John Soper; Andrew Berchuck; Ivan Spasojevic; Daniel L Clarke-Pearson; Leonard R Prosnitz; Mark Dewhirst
Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2005;21(4):333-47.
2005: G Larry Maxwell; Gadisetti V R Chandramouli; Louis A Dainty; Tracy Litzi; Andrew Berchuck; J Carl Barrett; John Risinger
Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4056-66.
2005: Livia Kelemen; Michael James; Amanda B Spurdle; Ian Campbell; Jenny Chang-Claude; David Peel; Hoda Anton-Culver; Andrew Berchuck; Joellen M Schildkraut; Alice Whittemore; Valerie McGurie; Richard A DiCioccio; David Duffy; Georgia Chenevix-Trench
BRAF polymorphisms and the risk of ovarian cancer of low malignant potential.
Gynecologic oncology 2005;97(3):807-12.
2005: Janiel M Cragun; Laura Havrilesky; Brian Calingaert; Ingrid Synan; Angeles Alvarez Secord; John Soper; Daniel L Clarke-Pearson; Andrew Berchuck
Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(16):3668-75.
2005: Andrew Berchuck; Edwin S Iversen; Johnathan M Lancaster; Jennifer Clarke; Jingqin Luo; Paula Lee; Susan Murphy; Holly K Dressman; Phillip G Febbo; Mike West; Joseph R Nevins; Jeffrey R Marks
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3686-96.
2005: John Soper; Laura Havrilesky; Angeles Alvarez Secord; Andrew Berchuck; Daniel L Clarke-Pearson
Rectus abdominis myocutaneous flaps for neovaginal reconstruction after radical pelvic surgery.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(3):542-8.
2005: John Soper; Angeles Alvarez Secord; Laura Havrilesky; Andrew Berchuck; Daniel L Clarke-Pearson
Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison of flap-related morbidity.
Gynecologic oncology 2005;97(2):596-601.
2005: Monique A Spillman; Joellen M Schildkraut; Susan Halabi; Patricia G Moorman; Brian Calingaert; Rex C Bentley; Jeffrey R Marks; Susan Murphy; Andrew Berchuck
Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk.
Gynecologic oncology 2005;97(2):543-9.
2005: Patricia G Moorman; Andrew Berchuck; Brian Calingaert; Susan Halabi; Joellen M Schildkraut
Antidepressant medication use [corrected] and risk of ovarian cancer.
Obstetrics and gynecology 2005;105(4):725-30.
2005: Robyn A Sayer; Johnathan M Lancaster; Jennifer Clarke; Jonathon Gray; Regina Whitaker; Jeffrey R Marks; Andrew Berchuck
High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.
Gynecologic oncology 2005;96(2):355-61.
2004: Andrew Berchuck; Joellen M Schildkraut; Robert M Wenham; Brian Calingaert; Shazia Ali; Amy Henriott; Susan Halabi; Gustavo Rodriguez; Dorota M Gertig; David M Purdie; Livia Kelemen; Amanda B Spurdle; Jeffrey Marks; Georgia Chenevix-Trench
Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2004;13(12):2141-7.
2004: Monique A Spillman; Andrew Berchuck
Stretching the surface epithelium.
Journal of the Society for Gynecologic Investigation 2004;11(8):501-2.
2004: Steven J Skates; Nora K Horick; Yinhua Yu; Feng-Ji Xu; Andrew Berchuck; Laura Havrilesky; Henk W A de Bruijn; Ate G J van der Zee; Robert P Woolas; Ian J Jacobs; Zhen Zhang; Robert C Bast
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(20):4059-66.
2004: Zhen Zhang; Robert C Bast; Yinhua Yu; Jinong Li; Lori J Sokoll; Alex J Rai; Jason Rosenzweig; Bonnie Cameron; Young Y Wang; Xiao-Ying Meng; Andrew Berchuck; Carolien Van Haaften-Day; Neville F Hacker; Henk W A de Bruijn; Ate G J van der Zee; Ian J Jacobs; Eric T Fung; Daniel W Chan
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.
Cancer research 2004;64(16):5882-90.
2004: Angeles Alvarez-Secord; Robyn A Sayer; Stacey A Snyder; Gloria Broadwater; Gustavo Rodriguez; Andrew Berchuck; Kimberly Blackwell
The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
Gynecologic oncology 2004;94(1):74-9.
2004: Karen H Lu; Andrea P Patterson; Lin Wang; Rebecca T Marquez; E Neely Atkinson; Keith A Baggerly; Lance R Ramoth; Daniel G Rosen; Jinsong Liu; Ingegerd Hellstrom; David Smith; Lynn Hartmann; David Fishman; Andrew Berchuck; Rosemarie Schmandt; Regina Whitaker; David M Gershenson; Gordon B Mills; Robert C Bast
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3291-300.
2004: Mara H Rendi; Nanjoo Suh; William W Lamph; Stan Krajewski; John C Reed; Richard A Heyman; Andrew Berchuck; Karen T Liby; Renee Risingsong; Darlene B Royce; Charlotte R Williams; Michael B. Sporn
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.
Cancer research 2004;64(10):3566-71.
2004: Andrew Berchuck; Edwin S Iversen; Johnathan M Lancaster; Holly K Dressman; Mike West; Joseph R Nevins; Jeffrey R Marks
Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.
American journal of obstetrics and gynecology 2004;190(4):910-25.
2004: Johnathan M Lancaster; Holly K Dressman; Regina S Whitaker; Laura Havrilesky; Jonathan Gray; Jeffrey R Marks; Joseph R Nevins; Andrew Berchuck
Gene expression patterns that characterize advanced stage serous ovarian cancers.
Journal of the Society for Gynecologic Investigation 2004;11(1):51-9.
2003: Laura Havrilesky; kathleen M Darcy; Hasnah Hamdan; Roger L Priore; Jorge Leon; Jeffrey Bell; Andrew Berchuck
Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(20):3814-25.
2003: Robert M Wenham; Joellen M Schildkraut; Kia McLean; Brian Calingaert; Rex C Bentley; Jeffrey Marks; Andrew Berchuck
Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4396-403.
2003: Janos L Tanyi; Yutaka Hasegawa; Ruth Lapushin; Andrew J Morris; Judith K Wolf; Andrew Berchuck; Karen Lu; David I Smith; Kimberly R Kalli; Lynn C Hartmann; Karen McCune; David Fishman; Russell R Broaddus; Kwai Wa Cheng; E Neely Atkinson; Jose-Miguel Yamal; Robert C Bast; Edward Felix; Robert A Newman; Gordon B Mills
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3534-45.
2003: Robert M Wenham; Brian Calingaert; Shazia Ali; Kia McClean; Regina Whitaker; Rex Bentley; Johnathan M Lancaster; Joellen M Schildkraut; Jeffrey Marks; Andrew Berchuck
Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer.
Journal of the Society for Gynecologic Investigation 2003;10(6):381-7.
2003: Laura Havrilesky; Bercedis L Peterson; Damla K Dryden; John Soper; Daniel L Clarke-Pearson; Andrew Berchuck
Predictors of clinical outcomes in the laparoscopic management of adnexal masses.
Obstetrics and gynecology 2003;102(2):243-51.
2003: Ellen Jones; Thaddeus V Samulski; Mark Dewhirst; Angeles Alvarez-Secord; Andrew Berchuck; Daniel L Clarke-Pearson; Laura Havrilesky; John Soper; Leonard R Prosnitz
A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma.
Cancer 2003;98(2):277-82.
2003: Laura Havrilesky; Terence Z Wong; Angeles Alvarez Secord; Andrew Berchuck; Daniel L Clarke-Pearson; Ellen Jones
The role of PET scanning in the detection of recurrent cervical cancer.
Gynecologic oncology 2003;90(1):186-90.
2003: Marilyn F Vine; Brian Calingaert; Andrew Berchuck; Joellen M Schildkraut
Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls.
Gynecologic oncology 2003;90(1):75-82.
2003: John Risinger; G Larry Maxwell; Andrew Berchuck; J Carl Barrett
Promoter hypermethylation as an epigenetic component in Type I and Type II endometrial cancers.
Annals of the New York Academy of Sciences 2003;983():208-12.
2003: Frédéric van den Brûle; Stéphane Califice; Frédérique Garnier; Pedro L Fernandez; Andrew Berchuck; Vincent Castronovo
Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin.
Laboratory investigation; a journal of technical methods and pathology 2003;83(3):377-86.
2003: Johnathan M Lancaster; Robert M Wenham; Susan Halabi; Brian Calingaert; Jeffrey R Marks; Patricia G Moorman; Rex C Bentley; Andrew Berchuck; Joellen M Schildkraut
No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2003;12(3):226-7.
2003: Johnathan M Lancaster; Robyn A Sayer; Carrie Blanchette; Brian Calingaert; Regina Whitaker; Joellen M Schildkraut; Jeffrey Marks; Andrew Berchuck
High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):762-6.
2003: Joe Gray; Seiji Suzuki; Wen-Lin Kuo; Daniel Polikoff; Michael Deavers; Karen Smith-McCune; Andrew Berchuck; Daniel Pinkel; Donna G Albertson; Gordon B Mills
Specific keynote: genome copy number abnormalities in ovarian cancer.
Gynecologic oncology 2003;88(1 Pt 2):S16-21; discussion S22-4.
2003: John Risinger; G Larry Maxwell; Gadisetti V R Chandramouli; Amir A Jazaeri; Olga Aprelikova; Tricia Patterson; Andrew Berchuck; J Carl Barrett
Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer.
Cancer research 2003;63(1):6-11.
2003: Laura Havrilesky; Angeles A Alvarez; Robyn A Sayer; Johnathan M Lancaster; John Soper; Andrew Berchuck; Daniel L Clarke-Pearson; Gustavo Rodriguez; Michael E Carney
Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
Gynecologic oncology 2003;88(1):51-7.
2002: Patricia G Moorman; Joellen M Schildkraut; Brian Calingaert; Susan Halabi; Marilyn F Vine; Andrew Berchuck
Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States).
Cancer causes & control : CCC 2002;13(9):807-11.
2002: Robert M Wenham; Johnathan M Lancaster; Andrew Berchuck
Molecular aspects of ovarian cancer.
Best practice & research. Clinical obstetrics & gynaecology 2002;16(4):483-97.
2002: Darlene Dixon; Gordon P Flake; Alicia B Moore; Hong He; Joseph K Haseman; John Risinger; Johnathan M Lancaster; Andrew Berchuck; J Carl Barrett; Stanley J Robboy
Cell proliferation and apoptosis in human uterine leiomyomas and myometria.
Virchows Archiv : an international journal of pathology 2002;441(1):53-62.
2002: Gustavo Rodriguez; Nimesh P Nagarsheth; Karen L Lee; Rex C Bentley; Walmer David; Mark Cline; Regina S Whitaker; Pam Isner; Andrew Berchuck; Richard K Dodge; Claude L Hughes
Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta.
Journal of the National Cancer Institute 2002;94(1):50-60.
2001: Carolien Van Haaften-Day; Y Shen; F Xu; Yinhua Yu; Andrew Berchuck; Laura Havrilesky; Henk W A de Bruijn; Ate G J van der Zee; Robert C Bast; Neville F Hacker
OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
Cancer 2001;92(11):2837-44.
2001: Laura Havrilesky; Angeles A Alvarez; Regina S Whitaker; Jeffrey R Marks; Andrew Berchuck
Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
Gynecologic oncology 2001;83(3):491-500.
2001: Marilyn F Vine; Roberta B Ness; Brian Calingaert; Joellen M Schildkraut; Andrew Berchuck
Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor.
Gynecologic oncology 2001;83(3):466-71.
2001: Jason Stout; Christopher W Woods; Angeles A Alvarez; Andrew Berchuck; C Dukes Hamilton
Mycobacterium bovis peritonitis mimicking ovarian cancer in a young woman.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33(4):E14-6.
2001: Angeles A Alvarez; AR Lambers; Johnathan M Lancaster; G Larry Maxwell; S Ali; Curtis Gumbs; Andrew Berchuck; P Andrew Futreal
Allele loss on chromosome 1p36 in epithelial ovarian cancers.
Gynecologic oncology 2001;82(1):94-8.
2001: Johnathan M Lancaster; John Risinger; Michael E Carney; J Carl Barrett; Andrew Berchuck
Mutational analysis of the PTEN gene in human uterine sarcomas.
American journal of obstetrics and gynecology 2001;184(6):1051-3.
2001: Laura Havrilesky; CP McMahon; Edward K Lobenhofer; Regina Whitaker; Jeffrey R Marks; Andrew Berchuck
Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones.
Journal of the Society for Gynecologic Investigation 2001;8(2):104-13.
2001: G Larry Maxwell; John Risinger; Angeles A Alvarez; J Carl Barrett; Andrew Berchuck
Favorable survival associated with microsatellite instability in endometrioid endometrial cancers.
Obstetrics and gynecology 2001;97(3):417-22.
2001: Angeles A Alvarez; WF Moore; Stanley J Robboy; Rex C Bentley; Curtis Gumbs; P Andrew Futreal; Andrew Berchuck
K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary.
Gynecologic oncology 2001;80(2):201-6.
2000: S Suzuki; Dan H Moore; David Ginzinger; Tony E Godfrey; J Barclay; B Powell; Daniel Pinkel; Charles J Zaloudek; K Lu; G Mills; Andrew Berchuck; Joe Gray
An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer.
Cancer research 2000;60(19):5382-5.
2000: G Larry Maxwell; John Risinger; K A Hayes; Angeles A Alvarez; Richard K Dodge; J Carl Barrett; Andrew Berchuck
Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):2999-3005.
2000: Hua Peng; F Xu; Rashmi Pershad; Kelly K Hunt; M L Frazier; Andrew Berchuck; Joe Gray; David Hogg; Robert C Bast; Yinhua Yu
ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers.
International journal of cancer. Journal international du cancer 2000;86(5):690-4.
2000: WF Moore; Rex C Bentley; Andrew Berchuck; Stanley J Robboy
Some mullerian inclusion cysts in lymph nodes may sometimes be metastases from serous borderline tumors of the ovary.
The American journal of surgical pathology 2000;24(5):710-8.
2000: P Bösze; R C Bast; Andrew Berchuck; Harry B Burke; R E Buller; William T Creasman; L Dubeau; Harold E Fox; HE Geisler; J P Geisler; D E Henson; G J Rustin; J B Vermorken; M Wells; G D Wilbanks
Conseusus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGO.
European journal of gynaecological oncology 2000;21(5):513-26.
2000: Joellen M Schildkraut; Susan Halabi; E Bastos; Polly A Marchbanks; J A McDonald; Andrew Berchuck
Prognostic factors in early-onset epithelial ovarian cancer: a population-based study.
Obstetrics and gynecology 2000;95(1):119-27.
2000: Mohamed Ahmed; K Kim; B Haddad; Andrew Berchuck; Mazin B Qumsiyeh
Comparative genomic hybridization studies in hydatidiform moles and choriocarcinoma: amplification of 7q21-q31 and loss of 8p12-p21 in choriocarcinoma.
Cancer genetics and cytogenetics 2000;116(1):10-5.
1999: Andrew Berchuck; Joellen M Schildkraut; Jeffrey R Marks; P Andrew Futreal
Managing hereditary ovarian cancer risk.
Cancer 1999;86(11 Suppl):2517-24.
1999: H Ashih; Tara Gustilo-Ashby; Evan Myers; J Andrews; Daniel L Clarke-Pearson; D Berry; Andrew Berchuck
Cost-effectiveness of treatment of early stage endometrial cancer.
Gynecologic oncology 1999;74(2):208-16.
1999: AR Lambers; Curtis Gumbs; S Ali; Jeffrey R Marks; J Dirk Iglehart; Andrew Berchuck; P Andrew Futreal
Bcl10 is not a target for frequent mutation in human carcinomas.
British journal of cancer 1999;80(10):1575-6.
1999: M R Brown; Rodrigo F Chuaqui; Cathy D Vocke; Andrew Berchuck; L P Middleton; Michael R Emmert-Buck; Elise C Kohn
Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors.
Gynecologic oncology 1999;74(1):98-102.
1999: Ronald P Zweemer; Patricia A Shaw; R M Verheijen; A Ryan; Andrew Berchuck; bruce ponder; Harvey A Risch; John R McLaughlin; Steven A Narod; Fred H Menko; Peter Kenemans; Ian J Jacobs
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
Journal of clinical pathology 1999;52(5):372-5.
1999: Zhen Zhang; SD Barnhill; H Zhang; F Xu; Yinhua Yu; I Jacobs; R P Woolas; Andrew Berchuck; KR Madyastha; Robert C Bast
Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses.
Gynecologic oncology 1999;73(1):56-61.
1999: Andrew Berchuck; Michael E Carney; P Andrew Futreal
Genetic susceptibility testing and prophylactic oophorectomy.
European journal of obstetrics, gynecology, and reproductive biology 1999;82(2):159-64.
1998: Olivier W H van der Heijden; H C Chiu; T C Park; H Takahashi; V A LiVolsi; John Risinger; J C Barrett; Andrew Berchuck; A C Evans; K Behbakht; AW Menzin; PC Liu; I Benjamin; Mark A Morgan; SA King; Stephen C Rubin; J Boyd
Allelotype analysis of uterine leiomyoma: localization of a potential tumor suppressor gene to a 4-cM region of chromosome 7q.
Molecular carcinogenesis 1998;23(4):243-7.
1998: John Risinger; K Hayes; G Larry Maxwell; Michael E Carney; R K Dodge; J Carl Barrett; Andrew Berchuck
PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(12):3005-10.
1998: Andrew Berchuck; K A Heron; Michael E Carney; Johnathan M Lancaster; E G Fraser; V L Vinson; Amie M Deffenbaugh; alexander miron; Jeffrey R Marks; P Andrew Futreal; Thomas S Frank
Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2433-7.
1998: Michael E Carney; G Larry Maxwell; Johnathan M Lancaster; Curtis Gumbs; Jeffrey Marks; Andrew Berchuck; P Andrew Futreal
Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers.
Journal of the Society for Gynecologic Investigation 1998;5(5):281-5.
1998: Robert C Bast; L Pusztai; B J Kerns; J A MacDonald; P Jordan; L Daly; CM Boyer; John Mendelsohn; Andrew Berchuck
Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues.
Hybridoma 1998;17(4):313-21.
1998: M P Boente; Andrew Berchuck; Regina S Whitaker; A Kalén; FJ Xu; Daniel L Clarke-Pearson; RM Bell; Robert C Bast
Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines.
Gynecologic oncology 1998;70(1):49-55.
1998: G Larry Maxwell; John Risinger; B Tong; Heather Shaw; J Carl Barrett; Andrew Berchuck; P Andrew Futreal
Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.
Gynecologic oncology 1998;70(1):13-6.
1998: Johnathan M Lancaster; Andrew Berchuck; Michael E Carney; Roger W Wiseman; J A Taylor
Progesterone receptor gene polymorphism and risk for breast and ovarian cancer.
British journal of cancer 1998;78(2):277.
1998: G Larry Maxwell; John Risinger; Curtis Gumbs; Heather Shaw; Rex C Bentley; J Carl Barrett; Andrew Berchuck; P Andrew Futreal
Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias.
Cancer research 1998;58(12):2500-3.
1998: Andrew Berchuck; Michael E Carney; Johnathan M Lancaster; Jeffrey Marks; A P Futreal
Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2.
Clinical obstetrics and gynecology 1998;41(1):157-66.
1997: Lester J Layfield; EA Saria; Andrew Berchuck; R K Dodge; J K Thompson; Debbi H Conlon; BJ Kerns
Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis.
Journal of surgical oncology 1997;66(4):230-6; discussion 236-7.
1997: Andrew Berchuck; J Schildkraut
Oral contraceptive pills. Prevention of ovarian cancer and other benefits.
North Carolina medical journal 1997;58(6):404-7; discussion 408.
1997: C Choi; S Cho; Izumi Horikawa; Andrew Berchuck; N Wang; E Cedrone; S W Jhung; J B Lee; J Kerr; G Chenevix-Trench; S Kim; J Carl Barrett; M Koi
Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas.
Genes, chromosomes & cancer 1997;20(3):234-42.
1997: John Risinger; A K Hayes; Andrew Berchuck; J Carl Barrett
PTEN/MMAC1 mutations in endometrial cancers.
Cancer research 1997;57(21):4736-8.
1997: Andrew Berchuck; M Carney
Human ovarian cancer of the surface epithelium.
Biochemical pharmacology 1997;54(5):541-4.
1997: J P Packenham; S du Manoir; E Schrock; John Risinger; Darlene Dixon; D N Denz; J A Evans; Andrew Berchuck; J Carl Barrett; Theodora R Devereux; T Ried
Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization.
Molecular carcinogenesis 1997;19(4):273-9.
1997: Joellen M Schildkraut; E Bastos; Andrew Berchuck
Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer.
Journal of the National Cancer Institute 1997;89(13):932-8.
1997: Johnathan M Lancaster; Andrew Berchuck; P Andrew Futreal; Roger W Wiseman
Dideoxy fingerprinting assay for BRCA1 mutation analysis.
Molecular carcinogenesis 1997;19(3):176-9.
1997: S L Clifford; C P Kaminetsky; Frank D Cirisano; Richard K Dodge; John Soper; Daniel L Clarke-Pearson; Andrew Berchuck
Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer.
American journal of obstetrics and gynecology 1997;176(6):S229-32.
1997: EE Mooney; Stanley J Robboy; Charles B Hammond; Andrew Berchuck; Rex C Bentley
Signet-ring cell carcinoma of the endometrium: a primary tumor masquerading as a metastasis.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 1997;16(2):169-72.
1997: Andrew Berchuck
Endometrial carcinoma and its precursors.
Current therapy in endocrinology and metabolism 1997;6():599-602.
1996: Stephen C Rubin; I Benjamin; K Behbakht; H Takahashi; Mark A Morgan; Virginia A LiVolsi; Andrew Berchuck; MG Muto; Judy E Garber; Barbara L Weber; Henry T Lynch; J Boyd
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
The New England journal of medicine 1996;335(19):1413-6.
1996: Johnathan M Lancaster; H A Brownlee; D A Bell; P Andrew Futreal; Jeffrey R Marks; Andrew Berchuck; Roger W Wiseman; J A Taylor
Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer.
Molecular carcinogenesis 1996;17(3):160-2.
1996: Matthew F Kohler; P Carney; R Dodge; John Soper; Daniel L Clarke-Pearson; Jeffrey R Marks; Andrew Berchuck
p53 overexpression in advanced-stage endometrial adenocarcinoma.
American journal of obstetrics and gynecology 1996;175(5):1246-52.
1996: FA van den Brule; C Buicu; Andrew Berchuck; R C Bast; Manuel Deprez; Fu-Tong Liu; D N Cooper; C Pieters; M E Sobel; Vincent Castronovo
Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma.
Human pathology 1996;27(11):1185-91.
1996: J P Vaughn; Frank D Cirisano; G Huper; Andrew Berchuck; P Andrew Futreal; Jeffrey R Marks; J Dirk Iglehart
Cell cycle control of BRCA2.
Cancer research 1996;56(20):4590-4.
1996: A A Elbendary; Frank D Cirisano; A C Evans; P L Davis; J Dirk Iglehart; Jeffrey R Marks; Andrew Berchuck
Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(9):1571-5.
1996: Andrew Berchuck; Frank D Cirisano; Johnathan M Lancaster; Joellen M Schildkraut; Roger W Wiseman; A Futreal; Jeffrey R Marks
Role of BRCA1 mutation screening in the management of familial ovarian cancer.
American journal of obstetrics and gynecology 1996;175(3 Pt 1):738-46.
1996: John Risinger; Asad Umar; J Boyd; Andrew Berchuck; Thomas A Kunkel; J Carl Barrett
Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair.
Nature genetics 1996;14(1):102-5.
1996: L A Terry; J Boyd; D Alcorta; T Lyon; G Solomon; G Hannon; Andrew Berchuck; D Beach; J Carl Barrett
Mutational analysis of the p21/WAF1/CIP1/SDI1 coding region in human tumor cell lines.
Molecular carcinogenesis 1996;16(4):221-8.
1996: J P Vaughn; P L Davis; Marcus D Jarboe; G Huper; A C Evans; Roger W Wiseman; Andrew Berchuck; J Dirk Iglehart; P Andrew Futreal; Jeffrey R Marks
BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996;7(6):711-5.
1996: Johnathan M Lancaster; Richard Wooster; J Mangion; CM Phelan; C Cochran; Curtis Gumbs; Sheila Seal; Rita Barfoot; N Collins; Graham R Bignell; S Patel; Rifat A Hamoudi; Catharina Larsson; Roger W Wiseman; Andrew Berchuck; J Dirk Iglehart; Jeffrey R Marks; Alan Ashworth; Michael R Stratton; P Andrew Futreal
BRCA2 mutations in primary breast and ovarian cancers.
Nature genetics 1996;13(2):238-40.
1996: Johnathan M Lancaster; C J Cochran; H A Brownlee; A C Evans; Andrew Berchuck; P Andrew Futreal; Roger W Wiseman
Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test.
Journal of the National Cancer Institute 1996;88(8):552-4.
1996: G Olt; John Soper; Sundaram Ramakrishnan; F Xu; Andrew Berchuck; Daniel L Clarke-Pearson; R Dodge; Robert C Bast
Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer.
American journal of obstetrics and gynecology 1996;174(4):1316-9.
1996: MP Boente; Thomas C Hamilton; A K Godwin; K Buetow; Matthew F Kohler; W M Hogan; Andrew Berchuck; R C Young
Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment.
Current problems in cancer 1996;20(2):83-137.
1996: Johnathan M Lancaster; Roger W Wiseman; Andrew Berchuck
An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene.
Obstetrics and gynecology 1996;87(2):306-9.
1996: Andrew Berchuck; Matthew F Kohler; R C Bast
Molecular genetic features of ovarian cancer.
Progress in clinical and biological research 1996;394():269-84.
1996: A M Hussein; William P Petros; Maureen Ross; James J Vredenburgh; M L Affrontil; R B Jones; E J Shpall; P Rubin; MA Elkordy; Colleen Gilbert; C Gupton; Merrill J Egorin; John Soper; Andrew Berchuck; D Clarke-Person; D A Berry; William P Peters
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies.
Cancer chemotherapy and pharmacology 1996;37(6):561-8.
1995: John Risinger; Asad Umar; Jayne C Boyer; A C Evans; Andrew Berchuck; Thomas A Kunkel; J Carl Barrett
Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity.
Cancer research 1995;55(23):5664-9.
1995: Andrew Berchuck; J Boyd
Molecular basis of endometrial cancer.
Cancer 1995;76(10 Suppl):2034-40.
1995: J A Hurteau; Robert P Woolas; Ian J Jacobs; D C Oram; C C Kurman; L A Rubin; D L Nelson; Andrew Berchuck; Robert C Bast; G B Mills
Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Cancer 1995;76(9):1615-20.
1995: A C Evans; John Soper; Daniel L Clarke-Pearson; Andrew Berchuck; Gustavo Rodriguez; C B Hammond
Gestational trophoblastic disease metastatic to the central nervous system.
Gynecologic oncology 1995;59(2):226-30.
1995: Andrew Berchuck; R C Bast
p53-based gene therapy of ovarian cancer: magic bullet?
Gynecologic oncology 1995;59(2):169-70.
1995: J Rebecca Liu; M Conaway; Gustavo Rodriguez; John Soper; Daniel L Clarke-Pearson; Andrew Berchuck
Relationship between race and interval to treatment in endometrial cancer.
Obstetrics and gynecology 1995;86(4 Pt 1):486-90.
1995: Andrew Berchuck; C Anspach; A C Evans; John Soper; Gustavo Rodriguez; Richard K Dodge; Stanley J Robboy; Daniel L Clarke-Pearson
Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma.
Gynecologic oncology 1995;59(1):20-4.
1995: Robert P Woolas; M R Conaway; F Xu; Ian J Jacobs; Y Yu; L Daly; A P Davies; KC O'Briant; Andrew Berchuck; John Soper
Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses.
Gynecologic oncology 1995;59(1):111-6.
1995: Matthew F Kohler; A Berkholz; John Risinger; A Elbendary; J Boyd; Andrew Berchuck
Mutational analysis of the estrogen-receptor gene in endometrial carcinoma.
Obstetrics and gynecology 1995;86(1):33-7.
1995: Laura Havrilesky; A Elbendary; J A Hurteau; Regina S Whitaker; Gustavo Rodriguez; Andrew Berchuck
Chemotherapy-induced apoptosis in epithelial ovarian cancers.
Obstetrics and gynecology 1995;85(6):1007-10.
1995: Joellen M Schildkraut; N K Collins; Georgette Dent; J A Tucker; J Carl Barrett; Andrew Berchuck; J Boyd
Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer.
American journal of obstetrics and gynecology 1995;172(3):908-13.
1995: Bruce A Lessey; Steven M Albelda; CA Buck; Arthur J Castelbaum; I-Tien Yeh; Matthew F Kohler; Andrew Berchuck
Distribution of integrin cell adhesion molecules in endometrial cancer.
The American journal of pathology 1995;146(3):717-26.
1995: John Soper; A C Evans; Gustavo Rodriguez; Andrew Berchuck; Daniel L Clarke-Pearson; C B Hammond
Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease.
Gynecologic oncology 1995;56(3):421-4.
1995: Laura Havrilesky; J A Hurteau; Regina S Whitaker; A Elbendary; S Wu; Gustavo Rodriguez; Robert C Bast; Andrew Berchuck
Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta.
Cancer research 1995;55(4):944-8.
1995: John Soper; Gustavo Rodriguez; Andrew Berchuck; Daniel L Clarke-Pearson
Long and short gracilis myocutaneous flaps for vulvovaginal reconstruction after radical pelvic surgery: comparison of flap-specific complications.
Gynecologic oncology 1995;56(2):271-5.
1995: Andrew Berchuck
Biomarkers in the ovary.
Journal of cellular biochemistry. Supplement 1995;23():223-6.
1995: Robert C Bast; CM Boyer; FJ Xu; J Wiener; R Dabel; Robert P Woolas; I Jacobs; Andrew Berchuck
Molecular approaches to prevention and detection of epithelial ovarian cancer.
Journal of cellular biochemistry. Supplement 1995;23():219-22.
1995: Andrew Berchuck
Biomarkers in the endometrium.
Journal of cellular biochemistry. Supplement 1995;23():174-8.
1994: John Soper; A C Evans; M R Conaway; Daniel L Clarke-Pearson; Andrew Berchuck; C B Hammond
Evaluation of prognostic factors and staging in gestational trophoblastic tumor.
Obstetrics and gynecology 1994;84(6):969-73.
1994: A Elbendary; Andrew Berchuck; P Davis; Laura Havrilesky; Robert C Bast; J Dirk Iglehart; Jeffrey R Marks
Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1994;5(12):1301-7.
1994: Gustavo Rodriguez; Claude L Hughes; John Soper; Andrew Berchuck; Daniel L Clarke-Pearson; C B Hammond
Serum progesterone for the exclusion of early pregnancy in women at risk for recurrent gestational trophoblastic neoplasia.
Obstetrics and gynecology 1994;84(5):794-7.
1994: Andrew Berchuck; A Elbendary; Laura Havrilesky; Gustavo Rodriguez; Robert C Bast
Pathogenesis of ovarian cancers.
Journal of the Society for Gynecologic Investigation 1994;1(3):181-90.
1994: John Soper; Daniel L Clarke-Pearson; Andrew Berchuck; Gustavo Rodriguez; C B Hammond
5-day methotrexate for women with metastatic gestational trophoblastic disease.
Gynecologic oncology 1994;54(1):76-9.
1994: J Hurteau; Gustavo Rodriguez; Regina S Whitaker; S Shah; G Mills; Robert C Bast; Andrew Berchuck
Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites.
Cancer 1994;74(1):93-9.
1994: John Risinger; Andrew Berchuck; Matthew F Kohler; J Boyd
Mutations of the E-cadherin gene in human gynecologic cancers.
Nature genetics 1994;7(1):98-102.
1994: A S Lukes; Matthew F Kohler; C F Pieper; B J Kerns; R Bentley; Gustavo Rodriguez; John Soper; Daniel L Clarke-Pearson; Robert C Bast; Andrew Berchuck
Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
Cancer 1994;73(9):2380-5.
1994: S Wu; W A Meeker; J R Wiener; Andrew Berchuck; Robert C Bast; CM Boyer
Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-alpha) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-alpha.
Gynecologic oncology 1994;53(1):59-63.
1994: J R Wiener; J A Hurteau; B J Kerns; Regina S Whitaker; M R Conaway; Andrew Berchuck; Robert C Bast
Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas.
American journal of obstetrics and gynecology 1994;170(4):1177-83.
1994: FJ Xu; YH Yu; L Daly; L Anselmino; G M Hass; Andrew Berchuck; Gustavo Rodriguez; John Soper; Daniel L Clarke-Pearson; D Hollis
OVX1 as a marker for early stage endometrial carcinoma.
Cancer 1994;73(7):1855-8.
1994: J R Wiener; B J Kerns; E L Harvey; M R Conaway; J Dirk Iglehart; Andrew Berchuck; Robert C Bast
Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression.
Journal of the National Cancer Institute 1994;86(5):372-8.
1994: Gustavo Rodriguez; Daniel L Clarke-Pearson; John Soper; Andrew Berchuck; I Synan; Richard K Dodge
The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer.
Obstetrics and gynecology 1994;83(3):445-8.
1994: Evan Myers; Daniel L Clarke-Pearson; G J Olt; John Soper; Andrew Berchuck
Preoperative coagulation testing on a gynecologic oncology service.
Obstetrics and gynecology 1994;83(3):438-44.
1994: B J Kerns; P A Jordan; L L Faerman; Andrew Berchuck; Robert C Bast; Lester J Layfield
Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis.
American journal of clinical pathology 1994;101(2):192-7.
1994: Andrew Berchuck; Matthew F Kohler; M P Hopkins; P A Humphrey; Stanley J Robboy; Gustavo Rodriguez; John Soper; Daniel L Clarke-Pearson; Robert C Bast
Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
Gynecologic oncology 1994;52(2):232-6.
1994: Andrew Berchuck; Matthew F Kohler; Jeffrey R Marks; Roger W Wiseman; J Boyd; Robert C Bast
The p53 tumor suppressor gene frequently is altered in gynecologic cancers.
American journal of obstetrics and gynecology 1994;170(1 Pt 1):246-52.
1994: F S Liu; Matthew F Kohler; Jeffrey R Marks; Robert C Bast; J Boyd; Andrew Berchuck
Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
Obstetrics and gynecology 1994;83(1):118-24.
1994: John Soper; A C Evans; Daniel L Clarke-Pearson; Andrew Berchuck; Gustavo Rodriguez; C B Hammond
Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease.
Obstetrics and gynecology 1994;83(1):113-7.
1994: Robert C Bast; F Xu; Y Yu; J Crews; Yair Argon; L Maier; Y Lidor; Andrew Berchuck; CM Boyer
Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer.
Immunology series 1994;61():23-30.
1994: Frédéric van den Brûle; Andrew Berchuck; R C Bast; Fu-Tong Liu; C Gillet; M E Sobel; Vincent Castronovo
Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas.
European journal of cancer (Oxford, England : 1990) 1994;30A(8):1096-9.
1993: Andrew Berchuck; R K Dodge
Interval to treatment in endometrial cancer.
American journal of obstetrics and gynecology 1993;169(6):1655-6.
1993: K A Leopold; J R Oleson; Daniel L Clarke-Pearson; John Soper; Andrew Berchuck; Thaddeus V Samulski; Rodney L Page; J Blivin; J K Tomberlin; Mark Dewhirst
Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma.
International journal of radiation oncology, biology, physics 1993;27(5):1245-51.
1993: A P Soisson; G Olt; John Soper; Andrew Berchuck; Gustavo Rodriguez; Daniel L Clarke-Pearson
Prevention of superficial wound separation with subcutaneous retention sutures.
Gynecologic oncology 1993;51(3):330-4.
1993: Robert P Woolas; FJ Xu; Ian J Jacobs; YH Yu; L Daly; Andrew Berchuck; John Soper; Daniel L Clarke-Pearson; David H Oram; Robert C Bast
Elevation of multiple serum markers in patients with stage I ovarian cancer.
Journal of the National Cancer Institute 1993;85(21):1748-51.
1993: John Risinger; Andrew Berchuck; Matthew F Kohler; P Watson; H T Lynch; J Boyd
Genetic instability of microsatellites in endometrial carcinoma.
Cancer research 1993;53(21):5100-3.
1993: Matthew F Kohler; Jeffrey R Marks; Roger W Wiseman; Ian J Jacobs; Andrew M Davidoff; Daniel L Clarke-Pearson; John Soper; Robert C Bast; Andrew Berchuck
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer.
Journal of the National Cancer Institute 1993;85(18):1513-9.
1993: Matthew F Kohler; H Nishii; P A Humphrey; H Saski; J Marks; Robert C Bast; Daniel L Clarke-Pearson; J Boyd; Andrew Berchuck
Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias.
American journal of obstetrics and gynecology 1993;169(3):690-4.
1993: MP Boente; J Hurteau; Gustavo Rodriguez; Robert C Bast; Andrew Berchuck
The biology of ovarian cancer.
Current opinion in oncology 1993;5(5):900-7.
1993: Y J Lidor; FJ Xu; O Martínez-Maza; G J Olt; J R Marks; Andrew Berchuck; Sundaram Ramakrishnan; J S Berek; Robert C Bast
Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells.
Experimental cell research 1993;207(2):332-9.
1993: FJ Xu; YH Yu; L Daly; Karen DeSombre; L Anselmino; G M Hass; Andrew Berchuck; John Soper; Daniel L Clarke-Pearson; C Boyer
OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(8):1506-10.
1993: S J McKenzie; Karen DeSombre; B S Bast; D R Hollis; Regina S Whitaker; Andrew Berchuck; CM Boyer; Robert C Bast
Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer.
Cancer 1993;71(12):3942-6.
1993: P A Jordan; B J Kerns; J C Pence; Matthew F Kohler; Robert C Bast; R B Kinney; Andrew Berchuck
Determination of proliferation index in advanced ovarian cancer using quantitative image analysis.
American journal of clinical pathology 1993;99(6):736-40.
1993: Matthew F Kohler; B J Kerns; P A Humphrey; Jeffrey R Marks; Robert C Bast; Andrew Berchuck
Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
Obstetrics and gynecology 1993;81(5 ( Pt 1)):643-50.
1993: H Sasaki; H Nishii; H Takahashi; A Tada; Masakuni Furusato; Y Terashima; G P Siegal; S L Parker; Matthew F Kohler; Andrew Berchuck
Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma.
Cancer research 1993;53(8):1906-10.
1993: S Wu; CM Boyer; Regina S Whitaker; Andrew Berchuck; J R Wiener; J Brice Weinberg; Robert C Bast
Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression.
Cancer research 1993;53(8):1939-44.
1993: Daniel L Clarke-Pearson; I S Synan; R Dodge; John Soper; Andrew Berchuck; R Edward Coleman
A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery.
American journal of obstetrics and gynecology 1993;168(4):1146-53; discussion 1153-4.
1993: Ian J Jacobs; S A Smith; Roger W Wiseman; P Andrew Futreal; T Harrington; R J Osborne; Vanessa Leech; A Molyneux; Andrew Berchuck; Bruce A J Ponder
A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus.
Cancer research 1993;53(6):1218-21.
1993: Robert C Bast; CM Boyer; I Jacobs; FJ Xu; S Wu; J Wiener; Matthew F Kohler; Andrew Berchuck
Cell growth regulation in epithelial ovarian cancer.
Cancer 1993;71(4 Suppl):1597-601.
1993: F Xu; R Lupu; Gustavo Rodriguez; Regina S Whitaker; MP Boente; Andrew Berchuck; Y Yu; Karen DeSombre; CM Boyer; Robert C Bast
Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.
International journal of cancer. Journal international du cancer 1993;53(3):401-8.
1993: Andrew Berchuck; Matthew F Kohler; MP Boente; Gustavo Rodriguez; Regina S Whitaker; Robert C Bast
Growth regulation and transformation of ovarian epithelium.
Cancer 1993;71(2 Suppl):545-51.
1993: G C Rodríguez; MP Boente; Andrew Berchuck; Regina S Whitaker; KC O'Briant; F Xu; Robert C Bast
The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines.
American journal of obstetrics and gynecology 1993;168(1 Pt 1):228-32.
1992: Ian J Jacobs; Matthew F Kohler; Roger W Wiseman; Jeffrey R Marks; R Whitaker; B A Kerns; P Humphrey; Andrew Berchuck; B A Ponder; Robert C Bast
Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation.
Journal of the National Cancer Institute 1992;84(23):1793-8.
1992: A P Soisson; John Soper; Andrew Berchuck; R Dodge; Daniel L Clarke-Pearson
Radical hysterectomy in obese women.
Obstetrics and gynecology 1992;80(6):940-3.
1992: MP Boente; Andrew Berchuck; Gustavo Rodriguez; A Davidoff; R Whitaker; FJ Xu; J Marks; Daniel L Clarke-Pearson; Robert C Bast
The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells.
American journal of obstetrics and gynecology 1992;167(6):1877-82.
1992: John Soper; P Johnson; V Johnson; Andrew Berchuck; Daniel L Clarke-Pearson
Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma.
Obstetrics and gynecology 1992;80(6):949-53.
1992: G Olt; Andrew Berchuck; A P Soisson; CM Boyer; Robert C Bast
Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer.
Cancer 1992;70(8):2137-42.
1992: J R Wiener; Andrew Berchuck; Robert C Bast
Biology and therapy with biologic agents in gynecologic cancer.
Current opinion in oncology 1992;4(5):946-54.
1992: Gustavo Rodriguez; John Soper; Andrew Berchuck; J Oleson; Richard K Dodge; Gustavo S Montana; Daniel L Clarke-Pearson
Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(10):1553-60.
1992: Andrew Berchuck; Matthew F Kohler; Robert C Bast
Oncogenes in ovarian cancer.
Hematology/oncology clinics of North America 1992;6(4):813-27.
1992: B J Kerns; P A Jordan; M B Moore; P A Humphrey; Andrew Berchuck; Matthew F Kohler; Robert C Bast; J Dirk Iglehart; Jeffrey R Marks
p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1992;40(7):1047-51.
1992: D Ignar-Trowbridge; John Risinger; Georgette Dent; Matthew F Kohler; Andrew Berchuck; john alan mclachlan; J Boyd
Mutations of the Ki-ras oncogene in endometrial carcinoma.
American journal of obstetrics and gynecology 1992;167(1):227-32.
1992: John Soper; Andrew Berchuck; R Dodge; Daniel L Clarke-Pearson
Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging.
Obstetrics and gynecology 1992;79(6):993-7.
1992: KC O'Briant; N Chrysson; V Hunter; F Tyson; M Tanner; L Daly; S L George; Andrew Berchuck; John Soper; Wesley C Fowler
Ha-ras polymorphisms in epithelial ovarian cancer.
Gynecologic oncology 1992;45(3):299-302.
1992: R C Bast; I Jacobs; Andrew Berchuck
Malignant transformation of ovarian epithelium.
Journal of the National Cancer Institute 1992;84(8):556-8.
1992: Matthew F Kohler; Andrew Berchuck; Andrew M Davidoff; P A Humphrey; Richard K Dodge; J Dirk Iglehart; John Soper; Daniel L Clarke-Pearson; Robert C Bast; Jeffrey R Marks
Overexpression and mutation of p53 in endometrial carcinoma.
Cancer research 1992;52(6):1622-7.
1992: Andrew Berchuck; MP Boente; Robert C Bast
The use of tumor markers in the management of patients with gynecologic carcinomas.
Clinical obstetrics and gynecology 1992;35(1):45-54.
1992: Andrew Berchuck; Gustavo Rodriguez; G Olt; R Whitaker; MP Boente; B A Arrick; Daniel L Clarke-Pearson; Robert C Bast
Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta.
American journal of obstetrics and gynecology 1992;166(2):676-84.
1992: Andrew Berchuck; M P Boente; B J Kerns; R B Kinney; John Soper; Daniel L Clarke-Pearson; Robert C Bast; S S Bacus
Ploidy analysis of epithelial ovarian cancers using image cytometry.
Gynecologic oncology 1992;44(1):61-5.
1991: FJ Xu; Sundaram Ramakrishnan; L Daly; John Soper; Andrew Berchuck; Daniel L Clarke-Pearson; Robert C Bast
Increased serum levels of macrophage colony-stimulating factor in ovarian cancer.
American journal of obstetrics and gynecology 1991;165(5 Pt 1):1356-62.
1991: John Soper; Andrew Berchuck; Daniel L Clarke-Pearson
Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging.
Cancer 1991;68(4):725-9.
1991: Jeffrey R Marks; Andrew M Davidoff; B J Kerns; P A Humphrey; J C Pence; Richard K Dodge; Daniel L Clarke-Pearson; J Dirk Iglehart; Robert C Bast; Andrew Berchuck
Overexpression and mutation of p53 in epithelial ovarian cancer.
Cancer research 1991;51(11):2979-84.
1991: John Soper; Grace M Couchman; Andrew Berchuck; Daniel L Clarke-Pearson
The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma.
Gynecologic oncology 1991;41(3):239-44.
1991: W Cliby; A P Soisson; Andrew Berchuck; Daniel L Clarke-Pearson
Stage I small cell carcinoma of the vulva treated with vulvectomy, lymphadenectomy, and adjuvant chemotherapy.
Cancer 1991;67(9):2415-7.
1991: Gustavo Rodriguez; Andrew Berchuck; Regina S Whitaker; D Schlossman; Daniel L Clarke-Pearson; Robert C Bast
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor.
American journal of obstetrics and gynecology 1991;164(3):745-50.
1991: Andrew Berchuck; Gustavo Rodriguez; A Kamel; R K Dodge; John Soper; Daniel L Clarke-Pearson; Robert C Bast
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.
American journal of obstetrics and gynecology 1991;164(2):669-74.
1991: John Soper; Andrew Berchuck; Daniel L Clarke-Pearson
The clinical significance of blood transfusion at the time of radical hysterectomy.
Obstetrics and gynecology 1991;77(1):165-6.
1991: Andrew Berchuck; Gustavo Rodriguez; R B Kinney; John Soper; R K Dodge; Daniel L Clarke-Pearson; Robert C Bast
Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease.
American journal of obstetrics and gynecology 1991;164(1 Pt 1):15-21.
1990: John Soper; Andrew Berchuck; G J Olt; A P Soisson; Daniel L Clarke-Pearson; Robert C Bast
Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma.
American journal of obstetrics and gynecology 1990;163(4 Pt 1):1204-9.
1990: Matthew F Kohler; Andrew Berchuck; M E Baker; C A Szpak; John Soper; Daniel L Clarke-Pearson
Computed tomography-guided fine-needle aspiration of retroperitoneal lymph nodes in gynecologic oncology.
Obstetrics and gynecology 1990;76(4):612-6.
1990: V J Hunter; L Daly; M Helms; John Soper; Andrew Berchuck; Daniel L Clarke-Pearson; Robert C Bast
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.
American journal of obstetrics and gynecology 1990;163(4 Pt 1):1164-7.
1990: E J Shpall; Daniel L Clarke-Pearson; John Soper; Andrew Berchuck; R B Jones; Robert C Bast; Maureen Ross; Y Lidor; K Vanacek; T Tyler
High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer.
Gynecologic oncology 1990;38(3):386-91.
1990: Andrew Berchuck; Gustavo Rodriguez; A Kamel; John Soper; Daniel L Clarke-Pearson; Robert C Bast
Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina.
Obstetrics and gynecology 1990;76(3 Pt 1):381-7.
1990: G Olt; Andrew Berchuck; Robert C Bast
The role of tumor markers in gynecologic oncology.
Obstetrical & gynecological survey 1990;45(9):570-7.
1990: A P Soisson; G Geszler; John Soper; Andrew Berchuck; Daniel L Clarke-Pearson
A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent cervical carcinoma after radical hysterectomy.
Obstetrics and gynecology 1990;76(1):106-9.
1990: Andrew Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; John Soper; Richard K Dodge; Daniel L Clarke-Pearson; P Marks
Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
Cancer research 1990;50(13):4087-91.
1990: A P Soisson; John Soper; Daniel L Clarke-Pearson; Andrew Berchuck; Gustavo S Montana; William T Creasman
Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer.
Gynecologic oncology 1990;37(3):390-5.
1990: Andrew Berchuck; G J Olt; A P Soisson; A Kamel; John Soper; CM Boyer; Daniel L Clarke-Pearson; D S Leslie; Robert C Bast
Heterogeneity of antigen expression in advanced epithelial ovarian cancer.
American journal of obstetrics and gynecology 1990;162(4):883-8.
1990: Andrew Berchuck; G J Olt; L Everitt; A P Soisson; Robert C Bast; CM Boyer
The role of peptide growth factors in epithelial ovarian cancer.
Obstetrics and gynecology 1990;75(2):255-62.
1990: Andrew Berchuck; S C Rubin; William J Hoskins; Patricia E Saigo; V K Pierce; J L Lewis
Treatment of endometrial stromal tumors.
Gynecologic oncology 1990;36(1):60-5.
1990: G J Olt; Andrew Berchuck; Robert C Bast
Gynecologic tumor markers.
Seminars in surgical oncology 1990;6(6):305-13.
1989: John Soper; D Larson; V J Hunter; Andrew Berchuck; Daniel L Clarke-Pearson
Short gracilis myocutaneous flaps for vulvovaginal reconstruction after radical pelvic surgery.
Obstetrics and gynecology 1989;74(5):823-7.
1989: A P Soisson; Andrew Berchuck; Bruce A Lessey; John Soper; Daniel L Clarke-Pearson; K S McCarty; Robert C Bast
Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels.
American journal of obstetrics and gynecology 1989;161(5):1258-63.
1989: Andrew Berchuck; A P Soisson; G J Olt; John Soper; Daniel L Clarke-Pearson; Robert C Bast; K S McCarty
Epidermal growth factor receptor expression in normal and malignant endometrium.
American journal of obstetrics and gynecology 1989;161(5):1247-52.
1989: Andrew Berchuck; PC MacDonald; L Milewich; ML Casey
Transforming growth factor-beta inhibits prostaglandin production in amnion and A431 cells.
Prostaglandins 1989;38(4):453-64.
1989: Andrew Berchuck; A P Soisson; John Soper; Daniel L Clarke-Pearson; Robert C Bast; K S McCarty
Reactivity of epidermal growth factor receptor monoclonal antibodies with human uterine tissues.
Archives of pathology & laboratory medicine 1989;113(10):1155-8.
1989: John Soper; Andrew Berchuck; William T Creasman; Daniel L Clarke-Pearson
Pelvic exenteration: factors associated with major surgical morbidity.
Gynecologic oncology 1989;35(1):93-8.
1989: L S Massad; K Santoriello; Andrew Berchuck
Pneumoperitoneum due to peritoneovaginal fistula following hysterectomy.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 1989;29(3):257-61.
1989: Andrew Berchuck; A P Soisson; Daniel L Clarke-Pearson; John Soper; CM Boyer; R B Kinney; K S McCarty; Robert C Bast
Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential.
Cancer research 1989;49(8):2091-5.
1989: RICARDO YAZIGI; Andrew Berchuck; M L Casey; P C MacDonald
Effect of epidermal growth factor on ornithine decarboxylase activity in A431 cells.
Anticancer research 1989;9(1):209-13.
1988: Andrew Berchuck; S C Rubin; William J Hoskins; Patricia E Saigo; V K Pierce; J L Lewis
Treatment of uterine leiomyosarcoma.
Obstetrics and gynecology 1988;71(6 Pt 1):845-50.
1988: Andrew Berchuck; PC MacDonald; L Milewich; ML Casey
Epidermal growth factor, vanadate, and 12-O-tetradecanoylphorbol-13-acetate inhibit growth and stimulate prostaglandin E2 production in A431 cells.
Molecular and cellular endocrinology 1988;57(1-2):87-92.
1985: Andrew Berchuck; T J Mullin
Cervical adenoid cystic carcinoma associated with ascites.
Gynecologic oncology 1985;22(2):201-11.
1984: Andrew Berchuck; Robert J Sokol
Cervicovaginal fistula formation: a new complication of Shirodkar cerclage.
American journal of perinatology 1984;1(3):263-5.
1983: Andrew Berchuck; Robert J Sokol
Previous cesarean section, placenta increta, and uterine rupture in second-trimester abortion.
American journal of obstetrics and gynecology 1983;145(6):766-7.